STOCK TITAN

Vanguard disaggregates holdings; ABT shows 0 shares (ABT)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Abbott Laboratories received an amended Schedule 13G/A from The Vanguard Group stating that, following an internal realignment, Vanguard and certain subsidiaries will report beneficial ownership separately. The filing lists Amount beneficially owned: 0 shares and Percent of class: 0% with an effective date shown as 03/13/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings; this filing reports no beneficial ownership in Abbott.

The filing states that, after an internal realignment described in the text, certain Vanguard subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The entry lists 0 shares and 0% as the reported position.

Dependencies include the internal allocation of holdings across Vanguard entities and the continued reliance on Release No. 34-39538. Subsequent filings from Vanguard may show separate beneficial ownership for related entities; timing and amounts for those separate reports are not included here.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026
Abbott Labs

NYSE:ABT

View ABT Stock Overview

ABT Rankings

ABT Latest News

ABT Latest SEC Filings

ABT Stock Data

180.82B
1.73B
Medical Devices
Pharmaceutical Preparations
Link
United States
ABBOTT PARK